Targeting cannabinoid agonists for inflammatory and neuropathic pain

Bibliography

• GAONI Y, MECHOULAM R: Isolation, structure, and partial synthesis of an active constituent of Hashish. J. Am. Chem. Soc. (1964) 86:1646-1647.
   Web of Science ®Google Scholar
• MUNRO S, THOMAS KL: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-65.
   PubMed Web of Science ®Google Scholar
• MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346:561-564.
   PubMed Web of Science ®Google Scholar
• HOWLETT AC, BARTH F, BONNER TI et al.: International Union of Pharmacology XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. (2002) 54:161-202.
   PubMed Web of Science ®Google Scholar
• DIAZ-LAVIADA I, RUIZ-LLORENTE L: Signal transduction activated by cannabinoid receptors. Mini-Rev. Med. Chem. (2005) 5:619-630.
   PubMed Web of Science ®Google Scholar
• DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptors. Science (1992) 258:1946-1949.
   PubMed Web of Science ®Google Scholar
• HANUS L, GOPHER A, ALMOG S, MECHOULAM R: Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. (1993) 36:3032-3034.
   PubMed Web of Science ®Google Scholar
• MECHOULAM R, BEN-SHABAT S, HANUS L et al.: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. (1995) 50:83-90.
   PubMed Web of Science ®Google Scholar
• STEINER H, BONNER TI, ZIMMER AM, KITAI ST, ZIMMER A: Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proc. Natl. Acad. Sci. USA (1999) 96:5786-5790.
   PubMed Web of Science ®Google Scholar
• VAN SICKLE MD, DUNCAN M, KINGSLEY PJ et al.: Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 310:329-332.
   PubMed Web of Science ®Google Scholar
• MANZANARES J, JULIAN MD, CARRASCOSA A: Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr. Neuropharmacol. (2006) 4:239-257.
   PubMed Web of Science ®Google Scholar
• FOX A, BEVAN S: Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin. Investig. Drugs (2005) 14(6):695-703.
   PubMed Web of Science ®Google Scholar
• BURNS TL, INECK JR: Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann. Pharmacother. (2006) 40:251-260.
   PubMed Web of Science ®Google Scholar
• FRIDE E, PERCHUK A, HALL FS, UHI GR, ONAIVI ES: Behavioral methods in cannabinoid research. Methods Mol. Med. (2006) 123:269-290.
   PubMedGoogle Scholar
• HANUS L, BREUER A, TCHILIBON S et al.: HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA (1999) 96(25):14228-14233.
   PubMed Web of Science ®Google Scholar
• MALAN TP Jr, IBRAHIM MM, DENG H et al.: CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 93:239-245.
   PubMed Web of Science ®Google Scholar
• YAO BB, MUKHERJEE S, FAN Y et al.: In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor. Br. J. Pharmacol. (2006) 149:145-154.
   PubMed Web of Science ®Google Scholar
• QUARTILHO A, HATA HP, IBRAHIM MM et al.: Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anasthesiology (2003) 99:955-960.
   PubMed Web of Science ®Google Scholar
• NACKLEY AG, MAKRIYANNIS A, HOHMANN AG: Selective activation of cannabinoid CB2 receptors suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 119:747-757.
   PubMed Web of Science ®Google Scholar
• HOHMANN AG, FARTHING JN, ZVONOK AM, MAKRIYANNIS A: Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J. Pharmacol. Exp. Ther. (2004) 308:446-453.
   PubMed Web of Science ®Google Scholar
• IBRAHIM MM, DENG H, ZVONOK A et al.: Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. USA (2003) 100(18):10529-10533.
   PubMed Web of Science ®Google Scholar
• BELTRAMO M, BERNARDINI N, BERTORELLI R et al.: CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci. (2006) 23:1530-1538.
   PubMed Web of Science ®Google Scholar
• IBRAHIM MM, RUDE ML, STAGG NJ et al.: CB2 cannabinoid receptor mediation of antinociception. Pain (2006) 122:36-42.
   PubMed Web of Science ®Google Scholar
• VALENZANO KJ, TAFESSE L, LEE G et al.: Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology (2005) 48:658-672.
   PubMed Web of Science ®Google Scholar
• CLAYTON N, MARSHALL FH, BOUNTRA C, O'SHAUGHNESSY CT: CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain (2002) 96:253-260.
   PubMed Web of Science ®Google Scholar
• WHITESIDE GT, GOTTSHALL SL, BOULET JM et al.: A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur. J. Pharmacol. (2005) 528:65-72.
   PubMed Web of Science ®Google Scholar
• HUFFMAN JW, LIDDLE J, YU S et al.: 3-(1′,1′-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem. (1999) 7:2905-2914.
   PubMed Web of Science ®Google Scholar
• ELMES SJR, WINYARD LA, MEDHURST SJ et al.: Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain (2005) 118:327-335.
   PubMed Web of Science ®Google Scholar
• ELMES S Jr, JHAVERI MD, SMART D et al.: Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. Eur. J. Neurosci. (2004) 20:2311-2320.
   PubMed Web of Science ®Google Scholar
• SAGAR DR, KELLY S, MILLNS, PJ, O'SHAUGHNESSEY CT, KENDALL DA, CHAPMAN V: Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur. J. Neurosci. (2005) 22:371-379.
   PubMed Web of Science ®Google Scholar
• MALAN TP Jr, IBRAHIM MM, LAI J, VANDERAH TW, MAKRIYANNIS A, PORRECA F: CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr. Opin. Pharmacol. (2003) 3:62-67.
   PubMed Web of Science ®Google Scholar
• IBRAHIM MM, PORRECA F, LAI J et al.: CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. USA (2005) 102:3093-3098.
   PubMed Web of Science ®Google Scholar
• NACKLEY AG, ZVONOK AM, MAKRIYAMMIS A, HOHMANN AG: Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J. Neurophysiol. (2004) 92:3562-3574.
   PubMed Web of Science ®Google Scholar
• ZHANG J, HOFFERT C, VU HK, GROBLEWSKI T, AHMAD S, O'DONELL D: Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci. (2003) 17:2750-2754.
   PubMed Web of Science ®Google Scholar
• WOTHERSPOON G, FOX A, McINTYRE S, COLLEY S, BEVAN S, WINTER J: Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience (2005) 135:235-245.
   PubMed Web of Science ®Google Scholar
• RICHARDSON JD, KILO S, HARGREAVES KM: Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain (1998) 75:111-119.
   PubMed Web of Science ®Google Scholar
• CALIGNANO A, LA RANA G, GIUFFRIDA A, PIOMELLI D: Control of pain initiation by endogenous cannabinoids. Nature (1998) 394:277-281.
   PubMed Web of Science ®Google Scholar
• KELLY S, JHAVERI MD, SAGAR DR, KENDALL DA, CHAPMAN V: Activation of peripheral cannabinoid CB1 receptors inhibits mechanically evoked responses of spinal neurons in non-inflamed rats and rats with hindpaw inflammation. Eur. J. Neurosci. (2003) 18:2239-2243.
   PubMed Web of Science ®Google Scholar
• AMAYA F, SHIMOSATO G, KAWASAKI Y et al.: Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain (2006) 124:175-183.
   PubMed Web of Science ®Google Scholar
• SHOWALTER VM, COMPTON DR, MARTIN BR, ABOOD ME: Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. (1996) 278:989-999.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE S, ADAMS M, WHITEAKER K et al.: Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. Eur. J. Pharmacol. (2004) 505:1-9.
   PubMed Web of Science ®Google Scholar
• JOHANEK LM, SOMONE DA: Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. Pain (2004) 109:432-442.
   PubMed Web of Science ®Google Scholar
• JOHANEK LM, HEITMILLER DR, TURNER M, NADER N, HODGES J, SIMONE D: Cannabinoids attenuate capsaicin-evoked hyeralgesia through spinal and peripheral mechanisms. Pain (2001) 93:303-315.
   PubMed Web of Science ®Google Scholar
• NACKLEY AG, SUPLITA RL, HOHMANN AG: A peripheral cannabinoid mechanism suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 117:659-670.
   PubMed Web of Science ®Google Scholar
• FOX A, KESINGLAND, A, GENTRY C et al.: The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain (2001) 92:91-100.
   PubMed Web of Science ®Google Scholar
• RUKWIED R, WATKINSON A, McGLONE F, DVORAK M: Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain (2003) 102:283-288.
   PubMed Web of Science ®Google Scholar
• FRIDE E, PONDE D, BREUER A, HANUS L: Peripheral, but not central effects of cannabidiol derivatives: mediation by CB1 and unidentified receptors. Neuropharmacology (2005) 28:1117-1129.
   Google Scholar
• FRIDE E, FEIGIN C, PONDE DE et al.: (+)-Cannabidiol analogues which bind cannabinoid recetpors but exert peripheral activity only. Eur. J. Pharmacol. (2004) 506:179-188.
   PubMed Web of Science ®Google Scholar
• SELTZMAN HH: Structure and receptor activity for classical cannabinoids. Curr. Med. Chem. (1999) 6:685-704.
   PubMed Web of Science ®Google Scholar
• HUFFMAN JW: CB2 receptor ligands. Mini-Rev. Med. Chem. (2005) 5:641-649.
   PubMed Web of Science ®Google Scholar
• RAITIO KH, SALO OMH, NEVALAINEN T, POSO A, JARVINEN T: Targeting the cannabinoid CB2 receptor: mutation, modeling and development of CB2 selective ligands. Curr. Med. Chem. (2005) 12:1217-1237.
   PubMed Web of Science ®Google Scholar
• PAVLOPOULOS S, THAKUR GA, NIKAS SP, MAKRIYANNIS A: Cannabinoid receptors as therapeutic targets. Curr. Pharm. Design (2006) 12:1751-1769.
   PubMed Web of Science ®Google Scholar
• ADAMS R, HARFENIST M, LOEWE S: New analogs of tetrahydrocannabinol. XIX. J. Am. Chem. Soc. (1949) 71:1624-1628.
   Web of Science ®Google Scholar
• HUFFMAN JW, MILLER JR, LIFFLE J et al.: Structure–activity relationships for 1′,1′-dimethylalkyl-Δ8-tetrahydro- cannabinols. Bioorg. Med. Chem. (2003) 11(7):1397-1410.
   PubMed Web of Science ®Google Scholar
• LU D, MENG Z, THAKUR GA et al.: Adamantyl cannabinoids: a novel class of cannabinergic ligands. J. Med. Chem. (2005) 48:4576-4585.
   PubMed Web of Science ®Google Scholar
• PAPAHATJIS DP, NAHMIAS VR, ANDREOU T, FAN P, MAKRIYANNIS A: Structural modifications of the cannabinoid side chain towards C3-aryl and 1′,1′-cycloalkyl- 1′-cyano cannabinoids. Bioorg. Med. Chem. Lett. (2006) 16:1616-1620.
   PubMed Web of Science ®Google Scholar
• GAREAU Y, DUFRESNE C, GALLANT M et al.: Structure–activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg. Med. Chem. Lett. (1996) 6(2):189-194.
   Web of Science ®Google Scholar
• MARRIOTT KC, HUFFMAN JW, WILLEY JL, MARTIN BR: Synthesis and pharmacology of 11-nor-1-methoxy-9- hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydro- cannabinols: new selective ligands for the cannabinoid CB2 receptor. Bioorg. Med. Chem. (2006) 14:2386-2397.
   PubMed Web of Science ®Google Scholar
• HUFFMAN HW, BUSHELL SM, JOSHI SN, WILEY JL, MARTIN BR: Enantioselective synthesis of 1-methoxy- and 1-dioxy-2′-methyl-D8 -tetrahydrocannabinols: new selective ligands for the CB2 receptor. Bioorg. Med. Chem. (2006) 14:247-262.
   PubMed Web of Science ®Google Scholar
• JOHNSON MR, MELVIN, LS: The discovery of nonclassical cannabinoid analgesics. In: Cannabinoids as Theraperutic Agents. Mechoulam R (Ed.), CRC Press, FL, USA (1986):121-145.
   Google Scholar
• HOWLETT AC, JOHNSON MR, MELVIN LS, MILNE GM: Nonclassical cannabinoid analgesics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. (1988) 33:297-302.
   PubMed Web of Science ®Google Scholar
• HUFFMAN JW, PADGETT LW: Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Cur. Med. Chem. (2005) 12:1395-1411.
   PubMed Web of Science ®Google Scholar
• D'AMBRA TE, EISSENSTAT MA, ABT J et al.: C-attached aminoalkylindoles: potent cannabinoid mimetics. Bioorg. Med. Chem. Lett. (1996) 6(1):17-22.
   Web of Science ®Google Scholar
• HUFFMAN JW, DAI D, MARTIN BR, MARTIN BR, COMPTON DR: Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg. Med. Chem. Lett. (1994) 4:563-566.
   Web of Science ®Google Scholar
• WILEY JL, COMPTON DR, DAI D et al.: Structure–activity relationships of indole- and pyrrole-derived cannabinoids. J. Pharmacol. Exp. Ther. (1998) 285:995-1004.
   PubMed Web of Science ®Google Scholar
• SHOWALTER VM, COMPTON DR, MARTIN BR, ABOOD ME: Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. (1996) 278:989-999.
   PubMed Web of Science ®Google Scholar
• HUFFMAN JW: The search for selective ligands for the CB2 receptor. Curr. Pharm. Design (2000) 6:1323-1337.
   PubMed Web of Science ®Google Scholar
• HUFFMAN JW, ZENGIN G, WU M et al.: Structure–activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. Bioorg. Med. Chem. (2005) 13:89-112.
   PubMed Web of Science ®Google Scholar
• HYNES J, LEFTHERIS K, WU H et al.: C-3 amido-indole cannabinoid receptor modulators. Bioorg. Med. Chem. Lett. (2002) 12:2399-2402.
   PubMed Web of Science ®Google Scholar
• WROBLESKI ST, CHEN P, HYNES J et al.: Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J. Med. Chem. (2003) 46:2110-2116.
   PubMed Web of Science ®Google Scholar
• PAGE D, BROCHU MC, YANG H et al.: Novel benzimidazole derivatives as selective CB2 inverse agonists. Lett. Drug Design Dis. (2006) 3:298-303.
   Web of Science ®Google Scholar
• ARMER R, WARNE P, WITHERINGTON J: Recent disclosures of clinical drug candidates. Drug. News Perspect. (2006) 19(1):65-72.
   PubMedGoogle Scholar
• MANERA C, BENETTI V, CASTELLI MP et al.: Design, synthesis and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J. Med. Chem. (2006) 49:5947-5957.
   PubMed Web of Science ®Google Scholar
• FERRARINI PL, CALDERONE V, CAVALLINI T et al.: Synthesis and biological evaluation of 1,8-nathphyridin- 4(1H)-on-3-carbozamide derivatives as new ligands of cannabinoid receptors. Bioorg. Med. Chem. (2004) 12:1921-1933.
   PubMed Web of Science ®Google Scholar
• TUCCINARDI T, FERRARINI PL, MANERA C, ORTORE G, SACCOMANNI G, MARTINELLI A: Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis. J. Med. Chem. (2006) 49:984-994.
   PubMed Web of Science ®Google Scholar
• STERN E, MUCCIOLI GG, MILLET R et al.: Novel 4-oxo-1,4-dihydroquinoline- 3-cabozamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. J. Med. Chem. (2006) 49:70-79.
   PubMed Web of Science ®Google Scholar
• FARQUHAR-SMITH WP: Peripheral cannabinoid analgesia: neuronal and immune mechanisms. Rev. Analgesia (2005) 8:103-116.
   Google Scholar